Important Information About



Increased Risk of Post-Transplant Lymphoproliferative Disorder (PTLD), predominantly involving the Central Nervous System (CNS), and Progressive Multifocal Leukoencephalopathy (PML) with NULOJIX

NULOJIX® is a selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids. NULOJIX is indicated for use only in patients who are Epstein-Barr virus (EBV) seropositive. Use of NULOJIX for the prophylaxis of organ rejection in other transplanted organs has not been established.

Increased Risk of Post-Transplant Lymphoproliferative Disorder (PTLD)

NULOJIX treated patients have an increased risk for PTLD, predominantly in the CNS

- The highest risk of PTLD is in EBV seronegative patients; therefore, NULOJIX is contraindicated in transplant recipients who are EBV seronegative or with unknown serostatus
- In clinical trials of kidney transplant recipients, PTLD was seen in 13 out of 949 NULOJIX-treated patients, including patients receiving the recommended dosage regimen and a dosage higher than the recommended regimen
  - —8 of 13 cases of PTLD in NULOJIX-treated patients presented in the CNS
  - —5 of those 8 CNS cases were fatal
- At the recommended clinical dose in the EBV seropositive population, 3 cases of PTLD were reported
  - —1 of those 3 cases presented in the CNS and that case was fatal
- Other known risk factors for PTLD include T-cell depleting therapy and cytomegalovirus (CMV) infection
  - —T-cell depleting therapy for the treatment of acute rejection should be used with caution in patients who are on NULOJIX
  - —CMV prophylaxis is recommended for at least 3 months after transplantation

Increased Risk of Progressive Multifocal Leukoencephalopathy (PML)

Patients in clinical trials exposed to NULOJIX at higher or more frequent dosing than the recommended regimen have developed PML

- 2 cases of PML were reported: 1 case occurred in a renal transplant recipient and 1 case occurred in a liver transplant recipient
- Do not exceed the recommended doses of NULOJIX and concomitant immunosuppressants

Patient Monitoring and Counseling

Monitor patients for new or worsening neurologic, cognitive, or behavioral signs or symptoms. If detected, consideration should be given to:

- Appropriate neurologic work-up including consideration for consultation with a specialist (e.g., neurologist and/or infectious disease)
- Dose reduction or discontinuation of immunosuppressive therapy taking into account the risk to the graft

Prescribers should counsel patients to:

- Immediately report changes in thinking, memory, speech, mood or behavior, confusion, weakness, change in vision, episodes of fever, night sweats, prolonged tiredness, weight loss, and swollen glands
- Adhere to all prescribed medications including those for prophylaxis

ENLiST Registry – Evaluating NULOJIX Long-Term Safety in Transplant

- BMS established the ENLiST Registry to further evaluate the safety profile of NULOJIX
- ENLiST is intended to enroll all adult kidney transplant patients who are treated with NULOJIX
- The primary objective of ENLiST is to determine the incidence of PTLD, CNS PTLD, and PML in US adult EBV seropositive kidney transplant recipients treated with NULOJIX
- Data collection will include the patients' EBV and CMV serostatus as well as when NULOJIX was initiated relative to time of transplant
- BMS encourages your center to participate in the ENLiST Registry. For more information on how to enroll in ENLiST and answers to other questions regarding the registry, please call 1-800-321-1335. Find out more about the protocol at www.clinicaltrials.gov

Adverse events with the use of NULOJIX should be reported to:

- Bristol-Myers Squibb at 1-800-721-5072 and/or
- FDA MedWatch program by phone at 1-800-FDA-1088 or online at www.fda.gov/medwatch/report.htm

All REMS materials, including a NULOJIX REMS webinar, are accessible at www.NULOJIX.com/REMS.aspx.

Please refer to the complete Prescribing Information for further information which is available at www.NULOJIX.com.

© 2011 Bristol-Myers Squibb
Printed in USA 721US11REMS00901 04/11

Approved 930043003 5.0